Skip to main content
. Author manuscript; available in PMC: 2016 Nov 1.
Published in final edited form as: Cancer Immunol Res. 2015 Jun 30;3(11):1248–1256. doi: 10.1158/2326-6066.CIR-15-0119

Table 2.

Adverse events

Grade 1
Grade 2
# events
(% doses)
# pts
(% of pts)
# events
(% doses)
# pts
(% of pts)
Likely/possibly related
  Injection site reaction 48 (18) 24 (71) 8 (2) 7 (21)
  Fever 1 (0.4) 1 (2.9) 0 (0) 0 (0)
  Flu-like symptoms 1 (0.4) 1 (2.9) 0 (0) 0 (0)
  Lymphocyte count decreased 4 (1.5) 2 (6) 2 (0.8) 2 (6)
  Joint effusion/joint swelling 1 (0.4) 1 (2.9) 0 (0) 0 (0)
  Myalgias/body aches 1 (0.4) 1 (2.9) 0 (0) 0 (0)
  Pruritus 1 (0.4) 1 (2.9) 0 (0) 0 (0)

Calculation based on 266 administered doses.

No events greater than Grade 2 attributed to vaccine.